Biotech companyLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field. in United StatesLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field.. FDA records under 2 spellings of its name, each linked to the record.
As of Nov 22, 2026, FDA's public records list Ultragenyx Pharmaceutical with 2 drug applications and 1 complete response letter. The most recent is a complete response letter dated Jul 7, 2025: Complete response letter, BL 125845.
Drug approvals, 510(k) clearances, recalls and letters, 2017 to 2026 to date
A hatched bar is a year that is not over, so its count covers only part of the year.
| Jul 7, 2025 | Complete response letter, BL 125845Unapproved | Complete response letter |
| Jun 30, 2020 | DojolviNDA 213687 | Drug application |
| Nov 15, 2017 | MepseviiBLA 761047 | Drug application |
What this company reported paying US doctors and teaching hospitals each year, $69.4M of it for research; see every company
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.